Exploring the Effects of Hand and Foot Exercise Intervention in Older Adults With Gynecological Cancer Receiving Chemotherapy Improvement of Peripheral Neuropathy and Quality of Life

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age65+
SponsorTaipei Veterans General Hospital, Taiwan

About this trial

Paclitaxel-based drugs are commonly used adjuvant chemotherapy for gynecological cancer patients. Peripheral neuropathy, a side effect of this treatment, presents with symptoms such as numbness, tingling, decreased skin and reflex sensation, and impaired function in the hands and feet, thus affecting quality of life. Peripheral neuropathy is a side effect caused by the neurotoxicity of certain chemotherapeutic drugs, including paclitaxel and platinum-based drugs, resulting from the cumulative toxicity of specific drug doses. While numerous international studies have confirmed the preventative effects of hand and foot movement interventions, there is a lack of relevant literature in China. Therefore, this study aims to explore the effects of hand and foot movement interventions on elderly gynecological cancer patients undergoing chemotherapy.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

None

Disqualifiers

None

Trial design

Design model

Parallel

Treatments tested in this trial

  • hand and foot exercises

    Other intervention

    The hand and foot exercise steps include hand and foot movements, practiced in a seated position. Hold each movement for ten seconds and then relax, repeating ten times. Perform the hand and foot exercises three times a day, for 10-15 minutes each time, three days a week, for twelve weeks.

Treatment groups

74 Participants
are divided into 2 treatment groups
Group A: control groupNo intervention 0 interventions
Group B: experimental groupExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Peripheral neuropathy

The content includes FACT/GOG-Ntx variable data.The maximum score is 120 points, and the minimum score is 0 points.A higher score indicates a better result.

Time frame
From enrollment to the end of treatment at 12 weeks.

Secondary outcomes

1

Quality of life

The content includes EORTC QLQ-CIPN20 variable data.The maximum score is 100 points, and the minimum score is 0 points. A higher score indicates a better quality of life.

Time frame
From enrollment to end of treatment (12 weeks)

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: